Prussian blue analogue-derived Co3O4/Fe2O3 with a partially hollow and octahedral structure for high-performance supercapacitors.

A supercapacitor (SC) is considered as a promising energy storage device because of its high power density, fast charging/discharging speed and long cycle life. The transition metal oxides prepared by traditional methods face some challenges, such as low conductivity and uncontrollable pore size distribution. Therefore, we have prepared Prussian blue analogues (PBAs) using a coprecipitation method. By adjusting additives in the experimental process, uniform PBAs with a series of regular morphologies and structures are successfully prepared. Then the corresponding metal oxides are obtained by calcining precursors. We systematically study the influence of the morphology and structure of metal oxides Co3O4/Fe2O3 derived from PBAs on their electrochemical performance. The metal oxide with a partially hollow and octahedral structure shows excellent electrochemical performance. In a neutral electrolyte, the specific capacitance is 659.7 F g-1 at a current density of 0.5 A g-1. After 6000 cycles, the capacitance retention rate is 63.7%. An asymmetric supercapacitor (ASC) is constructed using Co3O4/Fe2O3 with an octahedral structure (CFMO-PVP-2) as the positive electrode and YP-50F as the negative electrode. The maximum energy density is 31.4 W h kg-1 at a power density of 1921 W kg-1. The maximum power density is 8421 W kg-1 at an energy density of 23.5 W h kg-1. The excellent electrochemical performance is attributed to the low resistance (Rw and Rct) and high DOH- derived from the oxide particles on the surface and within the inner parts of the octahedron, which are available for electron transport. Meanwhile, the open void between adjacent nanoparticles allows the electrolyte ions to diffuse more efficiently and ensures a much more effective area for participating in a reaction. The strategy will give new insights into designing high-performance SCs based on PBAs.

OAB-14, a bexarotene derivative, improves Alzheimer's disease-related pathologies and cognitive impairments by increasing ß-amyloid clearance in APP/PS1 mice.

The pathogenesis of Alzheimer's disease (AD) is complex, though the clinical failures of anti-AD candidates targeting Aß production (such as ß- and γ-secretase inhibitors) make people suspect the Aß hypothesis, in which the neurotoxicity of Aß is undoubtedly involved. According to studies, >95% of AD patients with sporadic AD are primarily associated with abnormal Aß clearance. Therefore, drugs that increase Aß clearance are becoming new prospects for the treatment of AD. Here, the novel small molecule OAB-14, designed using bexarotene as the lead compound, significantly alleviated cognitive impairments in amyloid precursor protein (APP)/presenilin 1 (PS1) transgenic mice after administration for 15 days or 3 months. OAB-14 rapidly cleared 71% of Aß by promoting microglia phagocytosis and increasing IDE and NEP expression. This compound also attenuated the downstream pathological events of Aß accumulation, such as synaptic degeneration, neuronal loss, tau hyperphosphorylation and neuroinflammation in APP/PS1 mice. Moreover, OAB-14 had no significant effect on body weight or liver toxicity after acute and chronic treatment. OAB-14 was well tolerated and its maximum-tolerated dose in mice was >4.0 g/kg. Based on these findings, OAB-14 represents a promising new candidate for AD treatment.